Last reviewed · How we verify
TL-895
At a glance
| Generic name | TL-895 |
|---|---|
| Sponsor | Telios Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis (PHASE2)
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects (PHASE1, PHASE2)
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib (PHASE1, PHASE2)
- TL-895 and KRT-232 Study in Acute Myeloid Leukemia (PHASE1, PHASE2)
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF (PHASE1, PHASE2)
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis (PHASE2)
- A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TL-895 CI brief — competitive landscape report
- TL-895 updates RSS · CI watch RSS
- Telios Pharma, Inc. portfolio CI